ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

BIO applauds CMS for withdrawing problematic Part D proposals.

Print | 
Email |  Comment   Share  
March 18, 2014 - BIO has long been a supporter of the Medicare Part D prescription drug benefit program and commended Centers for Medicare & Medicaid Services for deciding to halt movement on several proposals in the Medicare Part D draft rule. They include: proposal to eliminate protected class status for certain drug classes, proposal to reduce the number of Part D plans a particular plan sponsor may offer, and proposal to clarify non-interference provisions.

BIO Applauds CMS for Withdrawing Problematic Part D Proposals

Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024

Press release date: March 10, 2014

WASHINGTON--Today, the Biotechnology Industry Organization (BIO) commended the Centers for Medicare & Medicaid Services (CMS) for announcing their decision to halt movement on several proposals in their Medicare Part D draft rule, including the agency’s proposal to eliminate protected class status for certain drug classes, as well as other proposals such as those related to reducing the number of Part D plans a particular plan sponsor may offer, and the proposal to clarify the non-interference provisions.

“BIO has long been a strong supporter of the Medicare Part D prescription drug benefit program.”

Equally importantly, BIO commends those in Congress, including members of the Senate Finance, House Energy & Commerce and House Ways & Means Committees, as well as others, who on a bipartisan basis urged CMS to withdraw either some or all of the draft rule.

If these proposals had been finalized, they would have eliminated choices for seniors, raised seniors’ premiums and out-of-pocket costs, and increased costs for taxpayers.

The following can be attributed to BIO President and CEO, Jim Greenwood:

“We applaud the Administration for withdrawing the most harmful provisions in this draft rule, and we applaud the Senate Finance Committee, House Ways and Means Committee, and the Energy and Commerce Committee in voicing strong, bipartisan opposition to the Proposed Rule, as the draft rule would have affected the most vulnerable patients. The priority must be ensuring timely access to medically necessary therapies and mitigating the risk of complications associated with an interruption of care for vulnerable Medicare beneficiaries.

“BIO has long been a strong supporter of the Medicare Part D prescription drug benefit program.

“We believe that the Part D benefit has helped increase patient access to critical therapies as well as ensure that patients will be able to receive and afford the treatments that best meet their needs.

“BIO will continue to work with the Congress to encourage CMS to focus on patient access in its ongoing implementation and refinement of this important program.”

BIO recently issued a comment letter outlining concerns with the Proposed Rule. For more information on the biotechnology industry, please visit

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter.” Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan

World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA

BIO International Convention
June 23-26, 2014
San Diego, CA

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

Biotechnology Industry Organization
Tracy Cooley, APR, 202-312-9274
Twitter: @IAmBiotech
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


Post a comment about this story

(your e-mail address will not be posted)
Comment title:
To submit comment, enter the security code shown below and press 'Post Comment'.

 See related product stories
More .....
 See more product news in:
| Featured Manufacturing Jobs
 Other News from this company:
BIO Issues Call for Sessions for 2015 BIO International Convention
2014 BIO Investor Forum Buzz of BIO Winners Announced
SDSU Offers Tours of Animal Research Facilities to Kick Off BIO's 2014 Livestock Biotech Summit
BIO Congratulates POET-DSM on Opening of Project Liberty
The 13th Annual BIO Investor Forum to Host Over 100 Presenting Companies
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story
Search for suppliers of
Trade Associations

Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy

Error close

Please enter a valid email address